Core Viewpoint - A recent study indicates that the combination of two cancer drugs, rapamycin and trametinib, can extend the lifespan of experimental mice by approximately 30% [1] Group 1: Research Findings - The study was conducted by the Max Planck Institute for Biology of Ageing in Germany and University College London [1] - The research was published in the latest issue of the journal "Nature Aging" [1] - Previous studies showed that trametinib alone could extend lifespan by 5%-10%, while rapamycin could achieve 15%-20% [1] Group 2: Synergistic Effects - The combination of rapamycin and trametinib produces a synergistic effect, resulting in a lifespan extension greater than the sum of their individual effects [1] - The treatment significantly improves the health status of older mice, with noticeable reductions in chronic inflammation in tissues and the brain [1] - The combination also delays the occurrence and progression of cancer in the treated mice [1]